Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial – TRIALS

Belotte, J; Felicetti, B; Baines, AJ; YoussefAgha, A; Rojas-Espaillat, L; Ortiz, AG; Provencher, D; Vazquez, RM; Cortijo, LG; Zeng, X – 2024 – 10.1186/s13063-024-08142-5

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial – JOURNAL OF NUCLEAR MEDICINE

Gebhart, G; Keyaerts, M; Guiot, T; Flamen, P; Ruiz-Borrego, M; Stradella, A; Bermejo, B; Escriva-de-Romani, S; Martínez, LC; Ribelles, N; Fernandez-Abad, M; Albacar, C; Colleoni, M; Garrigos, L; de Frutos, MA; Dalenc, F; Prat, A; Marmé, F; Schmid, P; Kerrou, K; Braga,...

Exploring the Relationship between MicroRNAs, Intratumoral Microbiota, and Breast Cancer Progression in Patients with and without Metastasis – INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Laborda-Illanes, A; Aranega-Martín, L; Sánchez-Alcoholado, L; Boutriq, S; Plaza-Andrades, I; Peralta-Linero, J; Ruiz, GG; Pajares-Hachero, B; Alvarez, M; Alba, E; González-González, A; Queipo-Ortuño, MI – 2024 – 10.3390/ijms25137091